# ABOS (Acumen Pharmaceuticals, Inc.) - SEC EDGAR Financial Statements

> Acumen Pharmaceuticals, Inc. reported $85.56M in total assets and a net loss of $104.0M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/ABOS
- Markdown: https://convexityos.com/fundamentals/ABOS.md
- SEC CIK: 0001576885
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:04 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001576885&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$104.7M | Operating profit |
| Net Income | FY 2025 | -$104.0M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$1.44 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$87.95M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $78.60M | Total debt: $26.31M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $104.9M | $93.80M | $42.32M | $32.36M | $12.30M | $8.00M |
| Total Operating Expenses | $123.8M | $114.0M | $61.14M | $45.24M | $19.58M | $9.35M |
| **Operating Income** | -$123.8M | -$114.0M | -$61.14M | -$45.24M | -$19.58M | -$7.91M |
| **EBITDA** | -$123.8M | -$114.0M | -$61.08M | -$45.20M | -$19.58M | -- |
| Interest Income | $7.45M | $14.32M | $10.79M | $2.39M | -- | -- |
| Interest Expense | $4.22M | $4.07M | $581K | $0 | -- | -- |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| **Net Income** | -$121.3M | -$102.3M | -$52.37M | -$42.86M | -$100.6M | -$7.33M |
| Basic EPS | -$2.00 | -$1.71 | -$1.08 | -$1.06 | -$5.02 | -$26.05 |
| **Diluted EPS** | -$2.00 | -$1.71 | -$1.08 | -$1.06 | -$5.02 | -$26.05 |
| Basic Shares Outstanding | 60.6M | 60.0M | 48.6M | 40.6M | 20.1M | 281.2K |
| Diluted Shares Outstanding | 60.6M | 60.0M | 48.6M | 40.6M | 20.1M | 281.2K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $21.11M | $27.81M | $16.48M | $20.53M | $21.97M | $37.12M | $25.27M | $34.57M |
| Total Operating Expenses | $25.81M | $32.56M | $21.15M | $25.20M | $26.51M | $41.75M | $30.37M | $39.60M |
| **Operating Income** | -$25.81M | -$32.56M | -$21.15M | -$25.20M | -$26.51M | -$41.75M | -$30.37M | -$39.60M |
| **EBITDA** | -$25.80M | -$32.55M | -$21.14M | -$25.19M | -$26.50M | -$41.73M | -$30.36M | -$39.58M |
| Interest Income | $812K | $1.11M | $1.06M | $1.32M | $1.64M | $2.02M | $2.47M | $2.99M |
| Interest Expense | $999K | $1.09M | $1.07M | $1.09M | $1.07M | $1.05M | $1.02M | $1.04M |
| **Net Income** | -$25.37M | -$32.72M | -$20.74M | -$25.14M | -$26.45M | -$40.95M | -$28.80M | -$37.15M |
| Basic EPS | -$0.35 | -$0.45 | -$0.33 | -- | -$0.44 | -$0.68 | -$0.48 | -- |
| **Diluted EPS** | -$0.35 | -$0.45 | -$0.33 | -- | -$0.44 | -$0.68 | -$0.48 | -- |
| Basic Shares Outstanding | 72.3M | 72.3M | 63.2M | -- | 60.6M | 60.6M | 60.5M | -- |
| Diluted Shares Outstanding | 72.3M | 72.3M | 63.2M | -- | 60.6M | 60.6M | 60.5M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $53.99M | $35.63M | $66.89M | $130.1M | $122.2M | $43.78M |
| Short-Term Investments | $62.88M | $135.9M | $176.6M | $47.50M | $72.08M | -- |
| **Cash & Short-Term Investments** | $116.9M | $171.6M | $243.5M | $177.6M | $194.2M | $43.78M |
| Other Current Assets | -- | -- | $283K | $237K | $140K | -- |
| **Total Current Assets** | $122.3M | $178.3M | $246.6M | $180.3M | $198.7M | $44.43M |
| Property, Plant & Equipment, Net | $103K | $73K | $122K | $165K | $36K | -- |
| Long-Term Investments | $0 | $59.97M | $62.55M | $15.84M | $31.62M | -- |
| Other Non-Current Assets | $350K | $486K | $724K | $151K | $14K | $0 |
| **Total Non-Current Assets** | $581K | $60.69M | $63.51M | $16.26M | $31.67M | $0 |
| **Total Assets** | $122.8M | $239.0M | $310.1M | $196.6M | $230.3M | $44.43M |
| Accounts Payable | $554K | $5.65M | $1.38M | $1.64M | $1.09M | $531K |
| Short-Term Debt | $8.77M | $0 | -- | -- | -- | -- |
| Other Current Liabilities | -- | -- | $212K | $131K | $204K | -- |
| **Total Current Liabilities** | $30.01M | $27.61M | $12.97M | $7.81M | $5.15M | -- |
| Long-Term Debt | -- | -- | $29.90M | $0 | -- | -- |
| Other Non-Current Liabilities | $0 | $150K | $284K | -- | -- | -- |
| **Total Non-Current Liabilities** | $22.40M | $29.57M | $30.18M | $0 | $0 | -- |
| **Total Liabilities** | $52.40M | $57.18M | $43.15M | $7.81M | $5.15M | $6.37M |
| **Total Debt (incl. Leases)** | $31.31M | $29.70M | $31.05M | $105K | -- | -- |
| Common Stock | $6.0K | $6.0K | $6.0K | $4.0K | $4.0K | -- |
| Retained Earnings | -$446.5M | -$325.1M | -$222.8M | -$170.4M | -$127.6M | -$26.96M |
| Accumulated Other Comp. Income | $83K | -$48K | $312K | -$751K | -- | -- |
| **Total Stockholders' Equity** | $70.43M | $181.8M | $267.0M | $188.8M | $225.2M | -$18.59M |
| Total Equity | $70.43M | $181.8M | $267.0M | $188.8M | $225.2M | -$18.59M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $53.08M | $59.44M | $51.80M | $53.99M | $46.83M | $36.81M | $30.16M | $35.63M |
| Short-Term Investments | $25.53M | $50.75M | $76.60M | $62.88M | $79.78M | $106.6M | $119.0M | $135.9M |
| **Cash & Short-Term Investments** | $78.60M | $110.2M | $128.4M | $116.9M | $126.6M | $143.4M | $149.1M | $171.6M |
| **Total Current Assets** | $85.13M | $115.5M | $133.1M | $122.3M | $132.2M | $148.4M | $154.9M | $178.3M |
| Property, Plant & Equipment, Net | $68K | $80K | $91K | $103K | $115K | $130K | $137K | $73K |
| Long-Term Investments | -- | -- | -- | $0 | $9.44M | $22.80M | $48.80M | $59.97M |
| Other Non-Current Assets | $200K | $263K | $304K | $350K | $393K | $464K | $504K | $486K |
| **Total Non-Current Assets** | $431K | $494K | $535K | $581K | $10.07M | $23.49M | $49.53M | $60.69M |
| **Total Assets** | $85.56M | $116.0M | $133.6M | $122.8M | $142.2M | $171.9M | $204.5M | $239.0M |
| Accounts Payable | $6.06M | $13.38M | $1.66M | $554K | $682K | $2.10M | $1.06M | $5.65M |
| Short-Term Debt | $20.40M | $19.67M | $14.12M | $8.77M | $3.60M | -- | -- | $0 |
| **Total Current Liabilities** | $45.09M | $46.85M | $29.23M | $30.01M | $21.96M | $24.86M | $19.32M | $27.61M |
| Long-Term Debt | -- | -- | -- | -- | -- | $29.88M | $29.53M | -- |
| Other Non-Current Liabilities | -- | -- | -- | $0 | $39K | $77K | $114K | $150K |
| **Total Non-Current Liabilities** | $5.87M | $11.90M | $16.92M | $22.40M | $27.09M | $29.96M | $29.64M | $29.57M |
| **Total Liabilities** | $50.95M | $58.74M | $46.15M | $52.40M | $49.05M | $54.82M | $48.96M | $57.18M |
| **Total Debt (incl. Leases)** | $26.31M | $31.65M | $31.16M | $31.31M | $30.84M | $30.10M | $29.78M | $29.70M |
| Common Stock | $7.0K | $7.0K | $7.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K |
| Retained Earnings | -$525.3M | -$499.9M | -$467.2M | -$446.5M | -$421.3M | -$394.9M | -$353.9M | -$325.1M |
| Accumulated Other Comp. Income | -$25K | -$13K | $21K | $83K | $109K | $23K | $15K | -$48K |
| **Total Stockholders' Equity** | $34.61M | $57.26M | $87.48M | $70.43M | $93.17M | $117.1M | $155.5M | $181.8M |
| Total Equity | $34.61M | $57.26M | $87.48M | $70.43M | $93.17M | $117.1M | $155.5M | $181.8M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$121.3M | -$102.3M | -$52.37M | -$42.86M | -$100.6M | -$7.33M |
| Depreciation & Amortization | $58K | $63K | $61K | $32K | $4.0K | -- |
| Stock-Based Compensation | $9.85M | $9.63M | $6.14M | $3.06M | $922K | $154K |
| Change in Payables | -$5.09M | $4.27M | -$261K | $552K | $557K | $308K |
| **Operating Cash Flow** | -$115.5M | -$86.22M | -$43.06M | -$35.15M | -$17.96M | -$7.45M |
| Capital Expenditure | -$88K | -$16K | -$21K | -$161K | -$40K | -- |
| **Free Cash Flow** | -$115.6M | -$86.23M | -$43.09M | -$35.31M | -$18.00M | -- |
| Purchases of Investments | -$38.06M | -$170.7M | -$250.6M | -$41.51M | -$104.1M | -- |
| **Investing Cash Flow** | $133.9M | $48.03M | -$171.7M | $39.19M | -$104.1M | -- |
| Common Stock Issued | $0 | $7.94M | $121.9M | $3.79M | $168.6M | -- |
| **Financing Cash Flow** | -$34K | $6.93M | $151.8M | $3.91M | $200.5M | $44.67M |
| **Net Change in Cash** | $18.36M | -$31.26M | -$62.98M | $7.94M | $78.39M | $37.23M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$25.37M | -$32.72M | -$20.74M | -$25.14M | -$26.45M | -$40.95M | -$28.80M | -$37.15M |
| Depreciation & Amortization | $12K | $11K | $12K | $12K | $15K | $16K | $15K | $14K |
| Stock-Based Compensation | $2.71M | $2.52M | $2.40M | $2.42M | $2.46M | $2.50M | $2.47M | $2.34M |
| Change in Payables | -$7.32M | $11.78M | $1.05M | -$128K | -$1.42M | $1.05M | -$4.59M | $3.31M |
| **Operating Cash Flow** | -$26.65M | -$18.07M | -$24.13M | -$19.10M | -$30.49M | -$31.83M | -$34.12M | -$27.21M |
| Capital Expenditure | $0 | $0 | $0 | $0 | $0 | -$9.0K | -$79K | $0 |
| **Free Cash Flow** | -$26.65M | -$18.07M | -$24.13M | -$19.10M | -$30.49M | -$31.84M | -$34.20M | -$27.21M |
| Purchases of Investments | $0 | $0 | -$40.82M | $0 | $0 | -$3.01M | -$35.05M | -$15.10M |
| **Investing Cash Flow** | $25.25M | $26.00M | -$13.81M | $26.25M | $40.51M | $38.48M | $28.69M | $29.66M |
| Common Stock Issued | -- | -- | -- | $0 | $0 | $0 | $0 | $0 |
| **Financing Cash Flow** | -$4.96M | -$278K | $35.74M | $2.0K | $0 | $0 | -$36K | -$9.0K |
| **Net Change in Cash** | -$6.37M | $7.65M | -$2.19M | $7.16M | $10.02M | $6.65M | -$5.47M | $2.44M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -172.3% | -56.3% | -19.6% | -22.7% | -44.7% | -- |
| Return on Assets (ROA) | -98.8% | -42.8% | -16.9% | -21.8% | -43.7% | -16.5% |
| Current Ratio | 4.07x | 6.46x | 19.01x | 23.08x | 38.60x | -- |
| Quick Ratio | 3.90x | 6.21x | 18.77x | 22.73x | 37.74x | -- |
| Debt to Equity | 0.44x | 0.16x | 0.12x | 0.00x | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -300.4% | -183.4% | -129.5% | -172.3% | -143.1% | -116.7% | -74.8% | -56.3% |
| Return on Assets (ROA) | -121.5% | -90.5% | -84.8% | -98.8% | -93.8% | -79.5% | -56.9% | -42.8% |
| Current Ratio | 1.89x | 2.47x | 4.55x | 4.07x | 6.02x | 5.97x | 8.02x | 6.46x |
| Quick Ratio | 1.74x | 2.35x | 4.39x | 3.90x | 5.77x | 5.77x | 7.72x | 6.21x |
| Debt to Equity | 0.76x | 0.55x | 0.36x | 0.44x | 0.33x | 0.26x | 0.19x | 0.16x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
